Progressive shares fall as Q3 earnings, revenue miss expectations
Director Raman Singh of Liquidia Corp (NASDAQ:LQDA) sold 7,500 shares of common stock on September 3, 2025, at a price of $29.42, totaling $220,650. The sale comes as the stock trades near its 52-week high of $29.94, having delivered an impressive return of over 218% in the past year. According to InvestingPro analysis, the stock’s technical indicators suggest it’s currently in overbought territory.
Following the transaction, Singh directly owns 31,255 shares of Liquidia Corp, which includes 18,396 restricted stock units granted on June 17, 2025, none of which have vested. The company, now valued at $2.49 billion, has shown strong momentum with a 145% gain year-to-date. For deeper insights into insider trading patterns and 14 additional key metrics, check out the comprehensive research available on InvestingPro.
In other recent news, Liquidia Technologies reported a significant revenue increase for the second quarter of 2025, with earnings reaching $8.8 million, far surpassing the projected $3.92 million. This surge was largely attributed to the strong sales performance of their product, Eutropia. Despite a larger-than-expected loss per share of $0.49 against a forecast of $0.42, the market responded positively. Jefferies has initiated coverage on Liquidia with a Buy rating and a $43 price target following the FDA approval of Yutrepia. BTIG also raised its price target for Liquidia to $49, citing stronger-than-expected patient adoption of Yutrepia, with over 900 unique prescriptions written. Raymond James adjusted its price target to $41, maintaining a Strong Buy rating due to positive metrics supporting Yutrepia’s launch. Wells Fargo increased its price target to $31, highlighting the robust launch performance of Liquidia’s product. These developments indicate a strong market response to Liquidia’s recent activities and product launches.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.